0.6248

0.03% -0.0002

Skye Bioscience Inc (SKYE)

Overview News Price History Discussions Forecast

Skye Bioscience Inc stock is traded at $0.6248, with a volume of 152.86K. It is down -0.03% in the last 24 hours and down -16.13% over the past month. Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Previous Close:

$0.625

Open:

$0.6297

24h Volume:

152.86K

Relative Volume:

0.24

Market Cap:

$20.86M

Revenue:

Net Income/Loss:

$-55.92M

P/E Ratio:

-0.4431

EPS:

-1.41

Net Cash Flow:

$-43.07M

1W Performance:

-7.19%

1M Performance:

-16.13%

6M Performance:

-82.64%

1Y Performance:

-73.53%

1-Day Range:

$0.6107

$0.6499

1-Week Range:

$0.6107

$0.6925

52-Week Range:

$0.61

$5.75

Skye Bioscience Inc Stock (SKYE) Company Profile

Name

Skye Bioscience Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(858) 410-0266

Address

11250 EL CAMINO REAL, SUITE 100, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-03-10

Latest SEC Filings

SKYE's Discussions on Twitter

Compare SKYE vs PSNYW, SHMD, GOODO, DWLD, QQQE

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SKYE Skye Bioscience Inc.	3.10	12.89M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	5.30	490.27M	2.07B	-1.42B	-1.37B	-0.6765
SHMD Schmid Group N V	7.42	364.76M	52.15M	-21.46M	0	-0.4675
GOODO Gladstone Commercial Corporation	19.92	372.90M	0	0	0	0.00
DWLD Davis Select Worldwide ETF	43.93	0	0	0	0	0.00
QQQE Direxion NASDAQ-100 Equal Weigh	99.50	0	0	0	0	0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-06-25	Downgrade	Craig Hallum	Buy → Hold
Aug-15-25	Initiated	Evercore ISI	Outperform
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform
Sep-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-09-24	Initiated	Craig Hallum	Buy
May-23-24	Initiated	Cantor Fitzgerald	Overweight
Apr-12-24	Initiated	Oppenheimer	Outperform

View All

Skye Bioscience Inc Stock (SKYE) Latest News

Mar 20, 2026

Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - The Globe and Mail

Mar 20, 2026

Skye Bioscience, Inc. Files Form 8-K Announcing Notice of Delisting or Failure to Satisfy Nasdaq Continued Listing Rule (March 2026) 5 - Minichart

Mar 20, 2026

Mar 19, 2026

Skye Bioscience receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com India

Mar 19, 2026

Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com

Mar 19, 2026

Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Mar 19, 2026

Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan

Mar 19, 2026

Mar 16, 2026

Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN

Mar 16, 2026

Mar 13, 2026

Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail

Mar 13, 2026

Mar 12, 2026

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail

Mar 12, 2026

Mar 11, 2026